A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs Ribociclib (Primary) ; Anastrozole; Goserelin; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms AMALEE
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 16 Oct 2024 Status changed from active, no longer recruiting to completed.
- 23 Sep 2024 This trial has been completed in Lithuania, according to European Clinical Trials Database record.
- 20 Sep 2024 This trial has been completed in France (Global end date: 2024-08-30) according to European Clinical Trials Database record.